Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 311-315

  Nitz, Alexandra ^a   Kontopantelis, Evangelos ^b   Bielack, Stefan ^c   Koscielniak, Ewa ^c   Klingebiel, Thomas ^d   Langer, Thorsten ^a   Paulides, Marios ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c OLGAHOSPITAL   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cancer; Child; Hearing; Late effects; Platinum compounds

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADULT; ARTICLE; AUDIOMETRY; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; HEARING; HEARING IMPAIRMENT; HUMAN; IRRADIATION; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OTOTOXICITY; PROSPECTIVE STUDY; SOFT TISSUE SARCOMA; TREATMENT WITHDRAWAL;

EID: 84869013977     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.997     Document Type: Article

References (32)

1. Bertolini P, Lassalle M, Mercier G, et al: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26: 649-655, 2004.
2. Skinner R: Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 40: 2352-2354, 2004.
3. Orgel E, Jain S, Ji L, et al: Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 58: 953-958, 2012
4. Pecora Liberman PH, Schultz C, Schmidt Goffi-Gomez MV, Antoneli CB, Motoro Chojniak M and Eduardo Novaes P: Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. Clin Transl Oncol 13: 348-352, 2011.
5. Stohr W, Langer T, Kremers A, et al: Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 23: 201-207, 2005.
6. Bokemeyer C, Berger CC, Hartmann JT, et al: Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355-1362, 1998.
7. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR and Pritchard J: Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19: 295-300, 1991.
8. Ilveskoski I, Saarinen UM, Wiklund T, et al: Ototoxicity in children with malignant brain tumors treated with the '8 in 1' chemotherapy protocol. Med Pediatr Oncol 27: 26-31, 1996.
9. Ruiz L, Gilden J, Jaffe N, Robertson R and Wang YM: Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II). Cancer Res 49: 742-744, 1989.
10. Schell MJ, McHaney VA, Green AA, et al: Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7: 754-760, 1989.
11. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM and Tattersall MH: Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66: 19-23, 1982.
12. Vermorken JB, Kapteijn TS, Hart AA and Pinedo HM: Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19: 53-58, 1983.
13. Macdonald MR, Harrison RV, Wake M, Bliss B and Macdonald RE: Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 23: 151-159, 1994.
14. Stohr W, Langer T, Kremers A, et al: Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System. Oncol Rep 12: 767-771, 2004.
15. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22: 669-674, 1998.
16. Langer T, Stöhr W, Paulides M, et al: Prospective multicenter registration of major late sequelae in sarcoma patients using the Late Effects Surveillance System (LESS). Klin Padiatr 217: 176-181, 2005.
17. Schmidt CM, Bartholomäus E, Deuster D, Heinecke A and Dinnesen AG: The 'Muenster classification' of high frequency hearing loss following cisplatin chemotherapy. HNO 55: 299-306, 2007 (In German).
18. Einarsson EJ, Petersen H, Wiebe T, et al: Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol 49: 765-771, 2010.
19. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al: Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47: 183-193, 2006.
20. Li Y, Womer RB and Silber JH: Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 40: 2445-2451, 2004.
21. Komune S, Asakuma S and Snow JB, Jr: Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 89: 275-282, 1981.
22. Pickel VM, Beckley SC, Joh TH and Reis DJ: Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res 225: 373-385, 1981.
23. Musial-Bright L, Fengler R, Henze G and Hernaiz Driever P: Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 27: 407-413, 2011.
24. Knight KR, Kraemer DF and Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23: 8588-8596, 2005.
25. Kushner BH, Budnick A, Kramer K, Modak S and Cheung NK: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107: 417-422, 2006.
26. Weatherly RA, Owens JJ, Catlin FI and Mahoney DH: Cis-platinum ototoxicity in children. Laryngoscope 101: 917-924, 1991.
27. Aguilar-Markulis NV, Beckley S, Priore R and Mettlin C: Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 16: 111-123, 1981.
28. Laurell G, Ekborn A, Viberg A and Canlon B: Effects of a single high dose of cisplatin on the melanocytes of the stria vascularis in the guinea pig. Audiol Neurootol 12: 170-178, 2007.
29. Marshall NE, Ballman KV, Michalak JC, et al: Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neurooncol 77: 315-320, 2006.
30. Simon T, Hero B, Dupuis W, Selle B and Berthold F: The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 214: 149-152, 2002.
31. Al-Khatib T, Cohen N, Carret AS and Daniel S: Cisplatinum ototoxicity in children, long-term follow up. Int J Pediatr Otorhinolaryngol 74: 913-919, 2010.
32. Laurell G and Jungnelius U: High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100: 724-734, 1990.